Share
Non-Small Cell Lung Cancer (NSCLC) Market By histology (large cell carcinoma, adenocarcinoma and SCC or squamous cell carcinoma); By treatment (chemotherapy, radiation and surgery)and Region -Analysis of Market Size, Share & Trends for 2014 - 2019 and Forecasts to 2030
Non-Small Cell Lung Cancer (NSCLC) Market to surpass USD 33.5 billion by 2030 from USD 12.4 billion in 2021 at a CAGR of 11.70% throughout the forecast period 2021-30.
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two main types of lung cancer NSCLC is the most common type of lung cancer accounting for approximately 85% of all lung cancers (IASLC, n.d.).Any epithelial lung cancer other than SCLC can be classified as NSCLC.NSCLC may be in the middle of the chest, but often also in other parts of the lung. Although NSCLCs are associated with smoking, they can also be found in patients who never have smoked. Adenocarcinomas are also common. Furthermore, chemotherapy and radiation therapy are fairly insensitive compared to SCLC.NSCLC comes from the central bronchial epithelial lung cells to the terminal alveoli. The histological type NSCLC coincides with the site of origin and reflects the variation in bronchial to alveoli respiratory epithelium. Whereas adenocarcinoma and bronchioloalveolar cancer typically originate from the peripheral lung tissue near central bronchuscommon symptoms include thoracic pain, wheezing, squatting, heartburn, chronic bronchitis, and loss of appetite, fatigue, shortness of respiration, bone pain, trouble swallowing, and limb stubbornness.
Non-Small Cell Lung Cancer (NSCLC) Market is expected to project a CAGR of 11.70% during the forecast period, 2021-2030
The Non-Small Cell Lung Cancer (NSCLC) market is anticipated to grow on the back of opportunities generated by the advent of the rising total number of lung cancer globally out of which Non-Small Cell Lung Cancer (NSCLC) holds a significant share. This has attracted the majority of the key leaders to focus on advancing therapeutics and increasing the efficiencies of the existing ones. This market is also driven by the existing status of lung cancer as the most widely occurring disease and the increase in the number of deaths it has caused. Also, an increase in the investments by the key leaders in research and developments and the introduction of Non-Small Cell Lung Cancer (NSCLC) therapeutics into the major market players is boosting the market globally.
The global Non-Small Cell Lung Cancer (NSCLC)market is based on histology
In the middle of the lungs in squamous cells, the SCC is found near the bronchus. Large or undifferentiated cell type carcinomas occur in every part of the lung, they grow rapidly and are not easily treated. Adenocarcinoma is found in the cells responsible for mucous secretion outside the lung and is slower in growth compared with both other types.
Market Dynamics
Rapid industrialization
Growing investment in the field of new drug research and development, rising emissions due to rapid industrialization, and increased smoker count are among the reasons why lung cancer is growing. This is why all of these factors drive market growth. According to a UK study from Cancer Research, the global incidence of cancer is increasing. The report shows that the cancer population will increase in the future. According to the report, there are expected to be 27.5 million new cancer cases in the world by 2040 if recent trends in the incidence of important cancers and population growth are consistent. This reflects a rise of 61.7% (17 million) compared to 2018. Thus, the incidence of NSCLC is expected to increase with the rise in cases of cancer. Increasing the demand for lung cancer therapeutics would help expand the market.
Targeted therapy resistance
Targeted therapy resistance is a major issue within the NSCLC market as its potential is greatly reduced at the start of the acquired therapy resistance like Tarceva or Xalkori (crizotinib). Although pipeline activity is limited at the late stage of new molecular goals, new drugs are available to target EGFR and ALK to control resistance to increase patients' timelines for targeted therapy
Rozlytrek (Entrectinib)
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
The Non-Small Cell Lung Cancer (NSCLC) Market size was estimated at USD 12.4 billion in 2021 and is expected to reach USD 33.5 billion by 2030
IBM Corporation, Health Fidelity, Wave Health Technologies, Lexalytics, Microsoft, Inovalon, AWS, Google, Dolby, and Cerner.
Histology and treatment are anticipated to hold the Non-Small Cell Lung Cancer (NSCLC) Market
Drivers Rapid industrialization
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two main types of lung cancer NSCLC is the most common type of lung cancer accounting for approximately 85% of all lung cancers (IASLC, n.d.).Any epithelial lung cancer other than SCLC can be classified as NSCLC.NSCLC may be in the middle of the chest, but often also in other parts of the lung.
Select License Type
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT
Working with Fatpos Global, allowed us to take advantage of their knowledge and easy approach, allowing us to collect important data utilizing a variety of techniques. The results were clearly presented and explained, and FG responded to our questions with speed and expertise.
|
Swiss-based global building materials manufacturer |
The analyses and presentations Fatpos Global have produced for us have been of a very high caliber and have allowed us to proactively improve our customer relationship management. They have also done so while maintaining complete anonymity. Without any doubt, we suggest Fatpos Global to you.
|
|
Tech-powered construction company |
We appreciate the team’s punctuality, flexibility in terms of report modification, post report purchase support and pleasant reaction all around. Overall, my experience with this company was nothing but positive, and I couldn't be more grateful for their excellent service. Thank you for all that you do!
|
|
American global management consulting firm |
We are able to concentrate on the topics and implications that are most important to our clients thanks to the adaptability and responsiveness of the team at Fatpos Global. We would highly recommend this company to anyone in need of their services, and I will certainly be using them again in the future.
|
|
Headquartered in Zug, Switzerland, leading supplier of medical and surgical instrument |
To better study our client demographics, develop the ideal product-price architecture, and enhance our target marketing initiatives, we hired Fatpos Global. Every component of the project was completed, and we are very happy with the useful insights and actionable results.
|
|
Kosovan company, A leading organic fertilizers producer |
Thank you for your team's generous assistance, The final report was delivered to me, and I find it to be really helpful. Also, you may be sure that I will get in touch with you if I ever require fresh materials for market research. Gratitude once more.
|
|
German specialty chemicals company based in Cologne, Germany |
